Disclosures for "Wearing-Off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening")
-
Mr. Clement has received personal compensation for serving as an employee of Novartis. Mr. Clement has stock in Roche.
-
Joanne Fielding, 24833 has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . The institution of Joanne Fielding, 24833 has received research support from BioEye. The institution of Joanne Fielding, 24833 has received research support from Equity Trustees. The institution of Joanne Fielding, 24833 has received research support from Macquarie Group Foundation. The institution of Joanne Fielding, 24833 has received research support from Genzyme. The institution of Joanne Fielding, 24833 has received research support from Biogen. The institution of Joanne Fielding, 24833 has received research support from Open Medicines Australia. The institution of Joanne Fielding, 24833 has received research support from EyeOnVision.
-
Ms. Serceau has nothing to disclose.
-
Ms. Robinson has nothing to disclose.
-
Chinmay Deshpande has received personal compensation for serving as an employee of Novartis Pharmaceutical Corporation . Chinmay Deshpande has stock in Novartis Pharmaceutical Corporation .